Novartis Buys Avidity For $12B To Expand Rare Disease Pipeline

Benzinga

Novartis will buy Avidity Biosciences for $12B in cash, expanding into rare muscle disorders. The deal includes a 46% premium and a Spinco spinoff, strengthening Novartis’ U.S. presence amid Trump’s proposed pharma tariffs.

Transcript

00:00It's Benzinga, bringing Wall Street to Main Street.

00:03Swiss drugmaker Novartis will acquire Avidity Biosciences for about $12 billion in cash

00:08to expand its portfolio in rare muscle disorders, according to Reuters.

00:13Avidity shareholders will receive $72 per share, a 46% premium to Friday's close.

00:19Novartis has been making acquisitions to offset upcoming patent expirations for its top-selling

00:24drugs.

00:25Avidity will spin off its early-stage precision cardiology programs into a new publicly traded

00:30company called Spinko.

00:32The deal bolsters Novartis' position in rare diseases and the U.S. market amid Trump's

00:37proposed pharmaceutical tariffs and follows recent acquisitions of Kate, Anthos, and Regulus

00:42Therapeutics.

00:43For all things money, visit Benzinga.com.

Category

Transcript

Be the first to comment

Recommended